Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Payables (2021 - 2025)

Bioregenx's Payables history spans 5 years, with the latest figure at $1.6 million for Q4 2025.

  • Quarterly results put Payables at $1.6 million for Q4 2025, up 23.53% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 23.53% YoY), and the annual figure for FY2025 was $1.6 million, up 23.53%.
  • Payables for Q4 2025 was $1.6 million at Bioregenx, up from $1.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.6 million in Q4 2025 to a low of $11996.0 in Q4 2021.
  • The 5-year median for Payables is $1.1 million (2024), against an average of $828603.1.
  • The sharpest move saw Payables surged 3394.4% in 2024, then decreased 21.92% in 2025.
  • Year by year, Payables stood at $11996.0 in 2021, then skyrocketed by 405.93% to $60691.0 in 2022, then soared by 917.24% to $617376.0 in 2023, then soared by 112.31% to $1.3 million in 2024, then rose by 23.53% to $1.6 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.6 million, $1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.